drugset / Trial / NCT00052572
Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders
Phase 2
Completed
35 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
Open-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ixabepilone in treating patients who have relapsed or refractory lymphoproliferative disorders.
Timeline
- Start
- 2002-10
- Primary completion
- —
- Completion
- 2007-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixabepilone | Small molecule | — | Intravenous |